Fund moves
7.3%Stake · was 7.3%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
GRI · NASDAQ · Pharmaceutical Preparations
Gri Bio (GRI) · oqro.io/stocks/GRI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Gri Bio was filed in the last 90 days. The latest on record was on Jun 4, 2021.
Since 2021, Gri Bio insiders reported 6 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2021.
No open-market sale by an insider of Gri Bio (GRI) was filed with the SEC in the last 90 days.
No trade in Gri Bio (GRI) was disclosed by a member of Congress in the last 12 months.
Gri Bio's next results are expected on Feb 2, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.12+0.00 (0.00%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−98.0% (−$56.00) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $57.12 on Nov 20, 2025 to $1.12 on Nov 20, 2026 (−98.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in La Jolla, Ca.
Last 12 months
−98.0%
Market value
$2.45M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 67K shares sold short (3.0% of shares outstanding), +0.6% vs the previous count, 1.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Gri Bio reported 6 open-market purchases and 0 sales since 2021; purchases in 2021.
| Year | Bought | Sold |
|---|---|---|
| 2021 | $105K6×6 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Notice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $9.47M, at Sep 30, 2026
Net income, last 12 months
−$7.81M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of May 14, 2026.
Revenue and earnings history, 6 fiscal yearsEarnings dates and the stock's moves
Last results
May 14, 2026
More than 30 days ago
Next results, expected
Feb 2, 2027
Purchases after results
Not enough history
From Gri Bio's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Gri Bio's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Latest annual report filed Jan 30, 2026, compared with the one filed Mar 14, 2025. Read the filing
We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results or financial condition. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have a material adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.
Source: SEC EDGAR, Form 10-K filed Jan 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. steatohepatitis, alcoholic liver disease, SLE, MS, ulcerative colitis patients as well as other indications. In these patients activated iNKT cells are correlated with more severe disease. We most recently evaluated GRI-0621 in a randomized, double-blind, multi-center, 2-arm Phase 2a clinical trial for the treatment of patients diagnosed with IPF.
And 17 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Jan 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 54.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (6.2% on ATS, 48.3% with other brokers), below its 26-week average of 62.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (29.7%), INSTINCT X (10.2%), UBS ATS (10.1%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.